[go: up one dir, main page]

BR9807319A - Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos. - Google Patents

Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.

Info

Publication number
BR9807319A
BR9807319A BR9807319-2A BR9807319A BR9807319A BR 9807319 A BR9807319 A BR 9807319A BR 9807319 A BR9807319 A BR 9807319A BR 9807319 A BR9807319 A BR 9807319A
Authority
BR
Brazil
Prior art keywords
microgranules
controlled release
oral administration
preparation
pharmaceutical preparation
Prior art date
Application number
BR9807319-2A
Other languages
English (en)
Inventor
Patrice Debregeas
Gerard Leduc
Pascal Oury
Pascal Suplie
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of BR9807319A publication Critical patent/BR9807319A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MICROGRâNULOS COM LIBERAçãO CONTROLADA, PARA ADMINISTRAçãO ORAL, CONTENDO CISPLATINA, PROCESSO DE PREPARAçãO DOS MESMOS, PREPARAçãO FARMACêUTICA, E, UTILIZAçãO DOS MICROGRâNULOS". A presente invenção refere-se a uma nova formulação de cisplatina, para administração oral, sob forma de microgrânulos com liberação controlada, assim como seu processo de preparação por montagem em meio aquoso. Ela se refere igualmente a uma preparação farmacêutica contendo microgrânulos de cisplatina com liberação controlada e um agente anti-canceroso como produto de combinação para uma utilização simultânea, separada ou escalonada no tempo em terapia anti-cancerosa, assim como a utilização dos referidos microgrânulos para fabricar um medicamento para administrar por via oral destinado a ser usado em poliquimioterapia ou em associação com uma radioterapia.
BR9807319-2A 1997-02-11 1998-02-10 Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos. BR9807319A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9701545A FR2759293B1 (fr) 1997-02-11 1997-02-11 Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
PCT/FR1998/000251 WO1998034599A1 (fr) 1997-02-11 1998-02-10 Microgranules contenant du cisplatine

Publications (1)

Publication Number Publication Date
BR9807319A true BR9807319A (pt) 2000-04-18

Family

ID=9503556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807319-2A BR9807319A (pt) 1997-02-11 1998-02-10 Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.

Country Status (24)

Country Link
US (2) US6458389B1 (pt)
EP (1) EP0971702B1 (pt)
JP (1) JP4549445B2 (pt)
KR (1) KR100471672B1 (pt)
AR (1) AR011133A1 (pt)
AT (1) ATE255409T1 (pt)
BG (1) BG64247B1 (pt)
BR (1) BR9807319A (pt)
CA (1) CA2282082C (pt)
DE (1) DE69820239T2 (pt)
DK (1) DK0971702T3 (pt)
EA (1) EA001760B1 (pt)
ES (1) ES2210726T3 (pt)
FR (1) FR2759293B1 (pt)
HU (1) HU225425B1 (pt)
IL (1) IL131326A (pt)
IN (1) IN187998B (pt)
NO (1) NO323230B1 (pt)
NZ (1) NZ337216A (pt)
PL (1) PL191631B1 (pt)
PT (1) PT971702E (pt)
TW (1) TW561055B (pt)
WO (1) WO1998034599A1 (pt)
ZA (1) ZA981123B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096304A1 (en) * 1998-09-08 2005-05-05 David White Method of treating cancer using dithiocarbamate derivatives
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
CN1164262C (zh) * 1999-05-17 2004-09-01 D.B.F.公司 含有植物物质的颗粒及其制备方法
CA2541578C (en) * 2003-10-10 2014-03-25 Ethypharm Sustained-release microgranules containing gingko biloba extract and the process for manufacturing these
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
MX2007005763A (es) * 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
EP1832293A4 (en) * 2004-12-10 2009-01-07 Tmrc Co Ltd MEANS FOR THE TREATMENT OF CANCER METASTAS AND CANNESMAS TREATMENT
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
JP5204846B2 (ja) * 2007-09-21 2013-06-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対して耐性を有する非オピオイド薬のｐＨ依存性制御放出医薬組成物
SI2187876T1 (sl) * 2007-09-21 2012-12-31 Evonik Roehm Gmbh Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola
CA2711473C (en) * 2008-01-10 2016-01-26 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
EP2231122A1 (en) * 2008-01-10 2010-09-29 Evonik Röhm GmbH Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
CA2688202C (en) * 2009-12-11 2012-11-13 Bj Services Company Viscoelastic fluids containing hydroxyethyl cellulose
EP2371356B1 (en) * 2010-03-12 2012-12-19 Phoeme GmbH Multi-particle pharmaceutical formulation for colon absorption
US8070047B1 (en) * 2010-12-02 2011-12-06 Rohm And Haas Electronic Materials Llc Flux composition and method of soldering
JP2015530387A (ja) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー 脂質複合体化シスプラチンによる肺癌の再発防止
JP6487534B2 (ja) 2014-09-05 2019-03-20 シンビオミックス セラピューティクス、エルエルシー 細菌性膣炎の治療に使用するためのセクニダゾール
US10238688B2 (en) * 2015-04-24 2019-03-26 Genedia Biotech Co., Ltd. Combination therapies for bladder cancer
CA2988082C (en) * 2015-06-01 2020-09-29 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
CN108024955A (zh) 2015-06-12 2018-05-11 瓦克萨特公司 用于rsv和诺如病毒抗原的小肠递送的制剂
TWI795462B (zh) 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
AU2019259686B2 (en) * 2018-04-24 2023-05-25 Shionogi & Co., Ltd. Solid formulation having excellent stability
JP6590436B1 (ja) * 2018-04-24 2019-10-16 塩野義製薬株式会社 安定性に優れた固形製剤
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059817B1 (fr) * 1981-03-11 1985-10-09 Mirko Beljanski Serpentine; alstonine et sempervirine, médicaments inhibant spécifiquement les cellules cancéreuses et tumorales
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
DE3523454A1 (de) * 1985-07-01 1987-01-08 Eberhard Prof Dr Nuernberg Formkoerper
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH05294839A (ja) * 1992-04-20 1993-11-09 Biomaterial Universe Kk シスプラチン含有生体内分解吸収性高分子の微小球お よびその製造法
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
JPH0789849A (ja) * 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
JPH0859460A (ja) * 1994-08-22 1996-03-05 Tanaka Kikinzoku Kogyo Kk 抗ガン剤内包キトサンミクロスフェア及びその製造法
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
JP2001501173A (ja) * 1996-08-23 2001-01-30 アルザ コーポレイション シスプラチン化合物を含有するリポソーム

Also Published As

Publication number Publication date
NO993881D0 (no) 1999-08-11
DK0971702T3 (da) 2004-04-13
IN187998B (pt) 2002-08-03
BG64247B1 (bg) 2004-07-30
ZA981123B (en) 1998-08-20
PL191631B1 (pl) 2006-06-30
JP2001512433A (ja) 2001-08-21
JP4549445B2 (ja) 2010-09-22
TW561055B (en) 2003-11-11
FR2759293B1 (fr) 1999-04-30
AU744001B2 (en) 2002-02-14
CA2282082C (fr) 2005-10-18
FR2759293A1 (fr) 1998-08-14
AU6626798A (en) 1998-08-26
HUP0001719A2 (hu) 2000-11-28
PL335107A1 (en) 2000-04-10
ATE255409T1 (de) 2003-12-15
EA199900734A1 (ru) 2000-04-24
IL131326A (en) 2005-03-20
EA001760B1 (ru) 2001-08-27
AR011133A1 (es) 2000-08-02
BG103647A (en) 2000-03-31
NO993881L (no) 1999-09-29
NZ337216A (en) 2000-09-29
PT971702E (pt) 2004-04-30
DE69820239D1 (de) 2004-01-15
HU225425B1 (en) 2006-11-28
US6458389B1 (en) 2002-10-01
CA2282082A1 (fr) 1998-08-13
IL131326A0 (en) 2001-01-28
EP0971702B1 (fr) 2003-12-03
HUP0001719A3 (en) 2005-11-28
US20030017210A1 (en) 2003-01-23
KR100471672B1 (ko) 2005-03-07
DE69820239T2 (de) 2004-10-07
KR20000070997A (ko) 2000-11-25
NO323230B1 (no) 2007-02-05
ES2210726T3 (es) 2004-07-01
EP0971702A1 (fr) 2000-01-19
WO1998034599A1 (fr) 1998-08-13

Similar Documents

Publication Publication Date Title
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
BR0211198A (pt) Composições farmacêuticas e seu uso
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
KR970025615A (ko) 암 전이 억제제
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
KR910005858A (ko) 지방산 요법
BRPI0407907A (pt) derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
KR920702225A (ko) 약학 조성물
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
CA2283739A1 (en) Ascorbic acid as an adjuvant in treatment of malignant tumors by chemotherapy and radiotherapy

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS REQUISITOS NOVIDADE ATIVIDADE INVENTIVA ( ARTS. 8O,10 ( VIII ), 13, 24 E 25 DA LPI 9279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]